Transplant characteristic
(reference level) |
Hazard
ratio |
95 % CI |
p |
Treatment group (Group 1) |
0.38 |
0.27 – 0.63 |
<0.001 |
Donor gender (male)
Female |
1.51 |
0.71 – 3.11 |
0.26 |
Recipient gender (male)
Female |
2.00 |
0.85 – 5.45 |
0.14 |
Recipient age at transplantation (35- 54) years
> 54 years |
0.72 |
0.33 – 1.51 |
0.34 |
Donor age (35- 54) years
> 54 years |
1.22 |
0.43 – 3.24 |
0.72 |
Renal disease (unspecified)
Glomerulonephritis
Interstitial nephritis
Polycystic kidney disease |
1.13
0.94
0.85 |
0.38 – 3.31
0.58 – 1.52
0.13 – 5.48 |
0.83
0.79
0.85 |
Pretransplant dialysis time (> 10 months)
3 – 10 months |
0.59 |
0.34 – 1.00 |
0.05 |
Pretransplant dialysis type (peritoneal dialysis)
Hemodialysis |
2.92 |
0.81 – 10.51 |
0.11 |
Donor source (living donor)
Deceased donor |
2.21 |
0.83 – 5.62 |
0.10 |
AR episode BD (no episode)
yes episode |
3.11 |
1.13 – 9.24 |
0.04 |
CMV proph/treat BD (no proph/treat)
yes proph/treat |
3.32 |
1.51 – 7.60 |
0.04 |
Immunosuppressive therapy (CyA,MMF,Cs)
Fk,MMF,Cs |
0.99 |
0.97 – 1.00 |
0.02 |
Development of PVAN (no)
yes |
3.52 |
1.63 – 7.52 |
< 0.01 |
Risk factors for major graft functional decline were a precedent AR episode,
a development of PVAN, a history of CMV prophylaxis/treatment before the
diagnosis of BKV-viremia, a maintenance immunosuppressive therapy based on
Fk, MMF, Cs versus a maintenance immunosuppressive therapy based on CyA,
MMF, Cs, a major duration of pretransplant dialysis ( > 10 months versus 3 – 10
months). Group 2 had approximately one third of major graft functional decline
than Group 1. Fk = tacrolimus, MMF = mycophenolate mofetil, Cs = steroid, CyA
= cyclosporine
e, ATG = antithymocyte globulins, CMV = cytomegalovirus, AR = acute rejection,
BD = before diagnosis. |
